Despite concerns raised by clinicians and ethicists, direct-to-consumer testing for Alzheimer’s disease biomarkers is here, ...

The FDA has started a priority review of Insmed's brensocatib, which is pitching to become the first approved therapy for bronchiectasis in the US.

Idorsia gets FDA approval of Tryvio (aprocitentan) for resistant hypertension, becoming the first drug in the endothelin receptor antagonist class for that use.